Compare · AZN vs XENE
AZN vs XENE
Side-by-side comparison of AstraZeneca PLC (AZN) and Xenon Pharmaceuticals Inc. (XENE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and XENE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $563.07B, about 113.7x XENE ($4.95B).
- Over the past year, AZN is down 3.6% and XENE is up 66.7% - XENE leads by 70.3 points.
- XENE has been more active in the news (23 items in the past 4 weeks vs 21 for AZN).
- AZN has more recent analyst coverage (25 ratings vs 19 for XENE).
- Company
- AstraZeneca PLC
- Xenon Pharmaceuticals Inc.
- Price
- $181.96+0.16%
- $52.46+2.44%
- Market cap
- $563.07B
- $4.95B
- 1M return
- -0.67%
- -7.07%
- 1Y return
- -3.59%
- +66.70%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2014
- News (4w)
- 21
- 23
- Recent ratings
- 25
- 19
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel modulator that is Phase III clinical trials for the treatment of KCNQ2 epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop FX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.
Latest AZN
- NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
- Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
- SEC Form 25-NSE filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest XENE
- Director Patou Gary sold $70,251 worth of shares (1,322 units at $53.14) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 24,896 units (SEC Form 4) to cover withholding tax
- Director Cannon Gillian sold $63,237 worth of shares (1,190 units at $53.14) as part of a pre-agreed trading plan, decreasing direct ownership by 45% to 1,455 units (SEC Form 4) to satisfy tax liability
- SEC Form 144 filed by Xenon Pharmaceuticals Inc.
- Director Patou Gary converted options into 2,645 shares, increasing direct ownership by 11% to 26,218 units (SEC Form 4)
- Director Machado Patrick converted options into 2,645 shares (SEC Form 4)
- Director Gover Justin D. converted options into 2,645 shares (SEC Form 4)
- Director Garofalo Elizabeth A. converted options into 2,645 shares (SEC Form 4)
- Director Gannon Steven converted options into 2,645 shares and covered exercise/tax liability with 1,416 shares, increasing direct ownership by 12% to 11,870 units (SEC Form 4) to cover withholding tax
- Director Cannon Gillian converted options into 2,645 shares (SEC Form 4)
- Director Svoronos Dawn converted options into 2,645 shares and covered exercise/tax liability with 1,416 shares, increasing direct ownership by 5% to 26,229 units (SEC Form 4) to satisfy withholding tax